5 Best Large-Cap Stocks to Buy in 2024

4. Merck & Co Inc (NYSE:MRK)

Number of Hedge Fund Investors: 85

Earlier this month Merck & Co Inc (NYSE:MRK) posted strong fourth quarter results. Adjusted EPS in the quarter came in at $0.03, surpassing estimates by $0.14. Revenue jumped 6% year over year to $14.6 billion, beating estimates by $120 million.

For full-year 2024 Merck & Co Inc (NYSE:MRK) expects adjusted EPS to come in the range of $8.44 and $8.59 versus the consensus estimate of $8.42 consensus.

Carillon Eagle Mid Cap Growth Fund made the following comment about Merck & Co., Inc. (NYSE:MRK) in its Q3 2023 investor letter:

“Merck & Co., Inc. (NYSE:MRK) underperformed in the third quarter, based on what we view as largely macroeconomic-related factors. The company continues to execute well, both clinically and fundamentally, but much of the biopharmaceutical industry has been weak as investors are gravitating to other, more cyclical sectors.”

1281292 - 11759070 - 1